Datopotamab deruxtecan: A novel antibody drug conjugate for triple-negative breast cancer

被引：10
|
作者：
Schipilliti, Francesca Matilde [1 ]
Drittone, Denise [1 ]
Mazzuca, Federica [2 ]
La Forgia, Daniele [3 ]
Guven, Deniz Can [4 ]
Rizzo, Alessandro [3 ]
机构：
[1] Univ Sapienza Rome, St Andrea Hosp, Oncol Dept, Rome, Italy
[2] Sapienza Univ, Dept Clin & Mol Med, Oncol Unit, Azienda Osped Univ St Andrea, Rome, Italy
[3] IRCCS Ist Tumori Giovanni Paolo II, Bari, Italy
[4] Hacettepe Univ, Dept Med Oncol, Canc Inst, TR-06100 Ankara, Turkiye
来源：
HELIYON | 2024年 / 10卷 / 07期
关键词：
Breast cancer; Triple -negative breast cancer; ADC; Antibody -drug conjugates; Dato-DXd; Datopotamab deruxtecan; TRASTUZUMAB EMTANSINE; SACITUZUMAB GOVITECAN; PHASE I/II; OPEN-LABEL; SURVIVAL; EFFICACY; TROP-2;
D O I：
10.1016/j.heliyon.2024.e28385
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Triple negative breast cancer (TNBC) represents the breast cancer subtype with least favorable outcome because of the lack of effective treatment options and its molecular features. Recently, ADCs have dramatically changed the breast cancer treatment landscape; the anti-TROP2 ADC Sacituzumab Govitecan has been approved for treatment of previously treated, metastatic TNBC patients. The novel ADC Datopotecan-deruxtecan (Dato-DXd) has recently shown encouraging results for TNBC. In the current paper, we summarize and discuss available data regarding this TROP-2 directed agent mechanism of action and pharmacologic activity, we describe first results on efficacy and safety of the drug and report characteristics, inclusion criteria and endpoints of the main ongoing clinical trials.
引用
收藏
页数：7
相关论文
共 50 条
  • [1] Safety evaluation of Datopotamab deruxtecan for triple-negative breast cancer: a meta-analysis
    Gadaleta-Caldarola, Gennaro
    Lanotte, Laura
    Infusino, Stefania
    Gadaleta-Caldarola, Arianna
    Schipilliti, Francesca Matilde
    Citrigno, Claudia
    Petrarota, Cataldo
    Cusmai, Antonio
    Rizzo, Alessandro
    CANCER TREATMENT AND RESEARCH COMMUNICATIONS, 2023, 37
  • [2] New Biomarkers in a Novel Antibody-Drug Conjugate for Triple-Negative Breast Cancer
    Nagayama, Aiko
    ONCOLOGIST, 2018, 23 : S5 - S5
  • [3] TROPION-Breast02: Datopotamab deruxtecan for locally recurrent inoperable or metastatic triple-negative breast cancer
    Dent, Rebecca A.
    Cescon, David W.
    Bachelot, Thomas
    Jung, Kyung Hae
    Shao, Zhi-Ming
    Saji, Shigehira
    Traina, Tiffany A.
    Vukovic, Petra
    Mapiye, Darlington
    Maxwell, Micah J.
    Schmid, Peter
    Cortes, Javier
    FUTURE ONCOLOGY, 2023, 19 (35) : 2349 - 2359
  • [4] Sacituzumab govitecan: a new antibody-drug conjugate for metastatic triple-negative breast cancer
    Banys-Paluchowski, M.
    Krawczyk, Natalia
    ONKOLOGE, 2021, 27 (03): : 287 - 290
  • [5] Anti-EGFR antibody-drug conjugate for triple-negative breast cancer therapy
    Si, Yingnan
    Xu, Yuanxin
    Guan, JiaShiung
    Chen, Kai
    Kim, Seulhee
    Yang, Eddy S.
    Zhou, Lufang
    Liu, Xiaoguang Margaret
    ENGINEERING IN LIFE SCIENCES, 2021, 21 (1-2): : 37 - 44
  • [6] Datopotamab deruxtecan (Dato-DXd), a TROP2-directed antibody-drug conjugate (ADC), for triple-negative breast cancer (TNBC): Preliminary results from an ongoing phase I trial
    Bardia, A.
    Juric, D.
    Shimizu, T.
    Tolcher, A.
    Karim, R.
    Spira, A.
    Mukohara, T.
    Lisberg, A. E.
    Kogawa, T.
    Krop, I.
    Papadopoulos, K. P.
    Hamilton, E.
    Damodaran, S.
    Greenberg, J.
    Gu, W.
    Kobayashi, F.
    Guevara, F.
    Jikoh, T.
    Kawasaki, Y.
    Meric-Bernstam, F.
    ANNALS OF ONCOLOGY, 2021, 32 : S60 - S60
  • [7] Antitumor effect of a novel humanized MUC1 antibody-drug conjugate on triple-negative breast cancer
    Li, Lan
    Cao, Jiawei
    Chen, Chunyan
    Qin, Yaqian
    He, Licai
    Gu, Haihua
    Wu, Guang
    HELIYON, 2023, 9 (04)
  • [8] Sacituzumab govitecan: antibody-drug conjugate in triple-negative breast cancer and other solid tumors
    Fenn, K. M.
    Kalinsky, K.
    DRUGS OF TODAY, 2019, 55 (09) : 575 - 585
  • [9] Antitumor activity of new antibody-drug conjugate with eribulin in triple-negative breast cancer PDX
    de Boisferon, Marc Hillairet
    Mignard, Caroline
    Durix, Coralie
    Uenaka, Toshimitsu
    Rybinski, Katherine
    Cheng, Xin
    Furuuchi, Keiji
    Albone, Eart
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [10] Antibody Drug Conjugates for Triple-Negative Breast Cancer: Targeting Positive in the Negative
    Bardia, Aditya
    ONCOLOGIST, 2017, 22 : S3 - S3
12345